公司简介

Exonics’ laboratory has demonstrated the ability to use adeno-associated virus (AAV) to deliver a payload based on CRISPR/Cas9 technology that can identify and correct exon mutations that prevent the production of dystrophin, a protein that helps stabilize and protect muscle fibers.

主要成员

Eric Olson、David Goeddel、Jj Kang、John Ripple

产品/服务

• 基因合成/编辑
• 遗传病诊断

SingleCutCRISPR

Correct the DNA sequence that causes the underlying disease.

Duchenne muscular dystrophy

Adeno-associated virus (AAV) to deliver the gene-editing enzyme CRISPR / Cas9.

融资信息

融资轮次	融资日期	投资方	融资额度
Seed	2017-02	CureDuchenne Ventures	500万美元
Series A	2017-11	The Column Group	4千万美元

关联公司